2 results
Approved WMOCompleted
To evaluate the safety, tolerability and pharmacokinetics of ascending single and multiple doses of CH-4051.
Approved WMORecruiting
Primary objectiveTo confirm superiority of oral semaglutide at the maximum tolerated dose* (3 mg, 7 mg or 14 mg) versus placebo on glycaemic control in children and adolescents (age 10 to <18 years) with type 2 diabetes on a background…